The Nextech team combines deep scientific knowledge with hands-on board leadership and investment experience in ways that truly add value. They quickly understood the scientific core and unique edge of our antibody-drug conjugate (ADC) platform and have been a strategic partner in navigating the challenges of building a leading oncology company from pre-clinical to clinical proof-of-concept.